Pulmonx Corp (LUNG) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Pulmonx Corp stock (LUNG) is currently trading at $1.30. Pulmonx Corp PS ratio (Price-to-Sales) is 0.65. Analyst consensus price target for LUNG is $5.17. WallStSmart rates LUNG as Sell.
- LUNG PE ratio analysis and historical PE chart
- LUNG PS ratio (Price-to-Sales) history and trend
- LUNG intrinsic value — DCF, Graham Number, EPV models
- LUNG stock price prediction 2025 2026 2027 2028 2029 2030
- LUNG fair value vs current price
- LUNG insider transactions and insider buying
- Is LUNG undervalued or overvalued?
- Pulmonx Corp financial analysis — revenue, earnings, cash flow
- LUNG Piotroski F-Score and Altman Z-Score
- LUNG analyst price target and Smart Rating
Pulmonx Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Pulmonx Corp (LUNG) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Pulmonx Corp (LUNG) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
81.82% of shares held by major funds and institutions
Trading at 1.06x book value, attractively priced
Supporting Valuation Data
Pulmonx Corp (LUNG) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -4.90%, a shrinking business
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Pulmonx Corp (LUNG) Detailed Analysis Report
Overall Assessment
This company scores 32/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 0.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Institutional Own., Price/Book. Valuation metrics including Price/Sales (0.65), Price/Book (1.06) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -4.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -77.20%, Operating Margin at -43.80%, Profit Margin at -59.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -77.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -4.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LUNG Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LUNG's Price-to-Sales ratio of 0.65x sits near its historical average of 0.74x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 29% below its historical high of 0.92x set in Mar 2026, and 0% above its historical low of 0.65x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Pulmonx Corp (LUNG) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Pulmonx Corp is in a turnaround phase, with management focused on restoring profitability. Revenue reached 90M with 5% decline year-over-year. The company is currently unprofitable, posting a -59.7% profit margin.
Key Findings
The company is unprofitable with a -59.7% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Pulmonx Corp.
Bottom Line
Pulmonx Corp is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(18 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 11:50:11 AM
About Pulmonx Corp(LUNG)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.